A5052009573- Cannabis and Cannabinoid Research
- Neurotransmitter Receptor Influence on Behavior
- Forensic Toxicology and Drug Analysis
- Neuroscience and Neuropharmacology Research
- Neuroendocrine regulation and behavior
- Psychedelics and Drug Studies
- Sleep and Wakefulness Research
- Stress Responses and Cortisol
- Epilepsy research and treatment
- Neuroscience of respiration and sleep
- Olfactory and Sensory Function Studies
- Sleep and related disorders
- Receptor Mechanisms and Signaling
- Bipolar Disorder and Treatment
- Schizophrenia research and treatment
- Substance Abuse Treatment and Outcomes
- Diet and metabolism studies
- Electroconvulsive Therapy Studies
- Pharmacological Effects and Toxicity Studies
- Prenatal Substance Exposure Effects
- Memory and Neural Mechanisms
- Biochemical Analysis and Sensing Techniques
- Neurological and metabolic disorders
- Alcohol Consumption and Health Effects
- Tryptophan and brain disorders
The University of Sydney
2016-2025
Swinburne University of Technology
2024
National Institute of Integrative Medicine
2022
Maastricht University
2021
Cooperative Trials Group for Neuro-Oncology
2021
RTI International
2018
University of New Orleans
2018
UNSW Sydney
2004-2017
Sax Institute
2016
King's College London
2015
There are no medications approved for treating cannabis dependence or withdrawal. The extract nabiximols (Sativex), developed as a multiple sclerosis treatment, offers potential agonist medication withdrawal.To evaluate the safety and efficacy of in withdrawal.A 2-site, double-blind randomized clinical inpatient trial with 28-day follow-up was conducted New South Wales, Australia. Participants included 51 DSM-IV-TR cannabis-dependent treatment seekers.A 6-day regimen (maximum daily dose,...
Indole and indazole synthetic cannabinoids (SCs) featuring l-valinate or l-tert-leucinate pendant group have recently emerged as prevalent recreational drugs, their use has been associated with serious adverse health effects. Due to the limited pharmacological data available for these compounds, 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, analogues were synthesized assessed cannabimimetic activity in vitro vivo. All SCs acted potent, highly efficacious agonists at...
Synthetic cannabinoid (SC) designer drugs based on indole and indazole scaffolds featuring l-valinamide or l-tert-leucinamide side chains are encountered with increasing frequency by forensic researchers law enforcement agencies associated serious adverse health effects. However, many of these novel SCs unprecedented in the scientific literature at time their discovery, little is known pharmacology. Here, we report synthesis pharmacological characterization AB-FUBINACA, ADB-FUBINACA,...
This study examined longitudinal trends in the dispensing of psychotropic medications Australia from January 2000 to December 2011.Dispensing data for major classes (antidepressants, anxiolytics, sedatives, antipsychotics, mood stabilisers and attention-deficit hyperactivity disorder (ADHD) medications) were obtained Drug Utilisation Sub-Committee Australian Department Health Ageing. Results expressed terms defined daily doses/1000 population/day (DDDs/1000/day).There was a 58.2% increase...
Synthetic cannabinoid (SC) designer drugs featuring bioisosteric fluorine substitution are identified by forensic chemists and toxicologists with increasing frequency. Although terminal fluorination of N-pentyl indole SCs is sometimes known to improve type 1 (CB1) receptor binding affinity, little the effects on functional activity SCs. This study explores in vitro activities SC JWH-018, UR-144, PB-22, APICA, their respective terminally fluorinated analogues AM-2201, XLR-11, 5F-PB-22,...
The main psychoactive component of cannabis, delta-9-tetrahydrocannabinol (THC), can impair driving performance. Cannabidiol (CBD), a non-intoxicating cannabis component, is thought to mitigate certain adverse effects THC. It possible then that containing equivalent CBD and THC will differentially affect cognition relative THC-dominant cannabis. present study investigated compared the THC/CBD on simulated cognitive In randomized, double-blind, within-subjects crossover design, healthy...
Although many studies have examined the acute behavioural effects of cannabinoids in rodents, few lasting at different developmental ages. This study compared cannabinoid exposure occurring adolescence to that early adulthood. Forty, 30-day old (adolescent) and 18, 56-day (adult) female albino Wistar rats were injected with vehicle or incremental doses receptor agonist (-)- cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]- trans-4-(3-hydroxypropyl) cyclohexanol (CP 55,940) once per day for 21...
Cat odor elicits a profound defensive reaction in rats that is reduced by benzodiazepine drugs. The neural correlates of this phenomenon were investigated here using Fos immunohistochemistry. Rats received either midazolam (0.75 mg/kg, s.c.) or vehicle and exposed to pieces collar had been worn domestic cat an unworn (dummy) collar. caused midazolam-sensitive behavioral responses, including avoidance contact, inhibition grooming, prolonged rearing. exposure induced expression the posterior...
There is mounting evidence that chronic cannabis use might result in lasting neurobehavioural changes, although it remains unclear whether vulnerability diminishes with age. The current study compared the effects of cannabinoid exposure at three developmental periods on subsequent measures memory and anxiety. Male rats aged 4 days (perinatal), 30 (adolescent) 56 (young adult) were injected vehicle or incremental doses receptor agonist CP 55940, daily for 21 consecutive (0.15, 0.20 0.30mg/kg...
Cannabis contains over 70 unique compounds and its abuse is linked to an increased risk of developing schizophrenia. The behavioural profiles the psychotropic cannabis constituent Δ9-tetrahydrocannabinol (Δ9-THC) non-psychotomimetic cannabidiol (CBD) were investigated with a battery tests relevant anxiety positive, negative cognitive symptoms Male adult C57BL/6JArc mice given 21 daily intraperitoneal injections vehicle, Δ9-THC (0.3, 1, 3 or 10 mg/kg) CBD (1, 5, 50 mg/kg). produced classic...
Recent analysis of the cannabinoid content cannabis plants suggests a shift towards use high potency plant material with levels Δ9-tetrahydrocannabinol (THC) and low other phytocannabinoids, particularly cannabidiol (CBD). Use this type is thought by some to predispose greater adverse outcomes on mental health fewer therapeutic benefits. Australia has one highest per capita rates in world yet there been no previous systematic being used. In present study we examined 206 samples that had...